Skip to main content
SleepCited

The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers.

Makoto Bannai, Nobuhiro Kawai, Kaori Ono, Keiko Nakahara, Noboru Murakami
Other Frontiers in neurology 2012 27 उद्धरण
PubMed DOI PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D22529837'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

अध्ययन प्रकार
Randomized Controlled Trial
हस्तक्षेप
The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Glycine 3 g before bedtime
तुलनित्र
Placebo
प्रभाव की दिशा
Positive
पूर्वाग्रह का जोखिम
Moderate

Abstract

Approximately 30% of the general population suffers from insomnia. Given that insomnia causes many problems, amelioration of the symptoms is crucial. Recently, we found that a non-essential amino acid, glycine subjectively and objectively improves sleep quality in humans who have difficulty sleeping. We evaluated the effects of glycine on daytime sleepiness, fatigue, and performances in sleep-restricted healthy subjects. Sleep was restricted to 25% less than the usual sleep time for three consecutive nights. Before bedtime, 3 g of glycine or placebo were ingested, sleepiness, and fatigue were evaluated using the visual analog scale (VAS) and a questionnaire, and performance were estimated by personal computer (PC) performance test program on the following day. In subjects given glycine, the VAS data showed a significant reduction in fatigue and a tendency toward reduced sleepiness. These observations were also found via the questionnaire, indicating that glycine improves daytime sleepiness and fatigue induced by acute sleep restriction. PC performance test revealed significant improvement in psychomotor vigilance test. We also measured plasma melatonin and the expression of circadian-modulated genes expression in the rat suprachiasmatic nucleus (SCN) to evaluate the effects of glycine on circadian rhythms. Glycine did not show significant effects on plasma melatonin concentrations during either the dark or light period. Moreover, the expression levels of clock genes such as Bmal1 and Per2 remained unchanged. However, we observed a glycine-induced increase in the neuropeptides arginine vasopressin and vasoactive intestinal polypeptide in the light period. Although no alterations in the circadian clock itself were observed, our results indicate that glycine modulated SCN function. Thus, glycine modulates certain neuropeptides in the SCN and this phenomenon may indirectly contribute to improving the occasional sleepiness and fatigue induced by sleep restriction.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

18SForward: CGCGGTTCTATTTTGTTGGTTTTCG
Reverse: CTGATCGTCTTCGAACCTCCGACTT
Bmal1Forward: AACCCGTGGACCAAGGAAGT
Reverse: GTGAGCTGTGGGAAGGTTGG
Per2Forward: CATGGCCAGTGTGCAGAGAG
Reverse: GAGGCCACCAAACAGACAGG
AVPForward: TCGCCATGATGCTCAACACT
Reverse: GCCTCCTCTTGGGCAGTTCT
VIPForward: GTTCCTGGCGATCCTGACAC
Reverse: AGGCCAGCGACTGTGAGAAC

Table 1

Results
Statistics
Placebo
Glycine
Treatment
Treatment × time
10:0014:0018:0010:0014:0018:00F1,6pF2,12p
VAS
Sleepiness; Sleepy: 100 – alert: 048.1 (5.65)52.9 (10.51)51 (6.97)32.7 (7.94)36 (6.78)45.6 (8.71)3.820.0980.260.774
Fatigue; Extremely fatigued: 100 – vigorous: 048.3 (4.97)53.1 (6.2)59.6 (8.14)33.6 (4.6)35.4 (8.62)51 (9.73)9.360.0220.480.628
QUESTIONNAIRE FOR FATIGUE COMPLAINTS
Factor I – drowsiness11.7 (1.46)11.7 (1.55)10.1 (1.79)8 (0.79)7.4 (0.84)8.9 (0.99)5.030.0660.380.691
Factor II – instability9.3 (0.84)9.6 (1.32)8 (1.13)6.6 (0.43)7 (1)7.6 (1.32)4.770.0723.350.07
Factor III – uneasiness9 (0.98)8.9 (1.18)9 (2.36)7.6 (0.43)7.4 (0.81)8.4 (1.02)1.550.2590.250.78
Factor IV – local pain or dullness7.7 (0.64)7.4 (0.53)7.1 (0.74)6.6 (0.57)6.4 (0.53)6.7 (0.47)3.160.1250.510.611
Factor V – eyestrains9.4 (1.51)8.9 (1.53)9.6 (1.17)7.4 (1.09)8 (1.18)8.4 (1.43)4.410.0810.610.559
Total score; extremely fatigued: 125 – vigorous: 2547 (4.24)46.1 (4.93)43.7 (6.17)36.1 (1.75)36.3 (3.21)40 (4.21)4.440.081.20.334

Table 2

Day 1
Day 3
Treatment
Treatment × time
Treatment
Treatment × time
F1,6pF2,12pF1,6pF2,12p
SIMPLE REACTION TIME TEST
Correct response1.350.2890.180.838.1.360.2881.40.284
Reaction time3.780.11.780.2110.020.8921.090.369
PSYCHOMOTOR VIGILANCE TEST
Correct response2.840.1431.410.2830.40.550.710.513
Reaction time21.690.0030.660.5366.010.050.070.937
MEMORY RECOGNITION TEST
Correct response4.570.0762.650.1111.540.2614.080.044
Reaction time1.70.2410.3970.730.4260.530.602
NUMBER ADDITION TEST
Correct response0.00040.9842.10.1650.550.4860.890.435
Reaction time0.050.8380.190.8310.070.7951.320.304

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled
  27. Untitled
  28. Untitled
  29. Untitled
  30. Untitled
  31. Untitled
  32. Untitled
  33. Untitled
  34. Untitled
  35. Untitled
  36. Untitled
  37. Untitled
  38. Untitled
  39. Untitled
  40. Untitled
  41. Untitled
  42. Untitled
  43. Untitled
  44. Untitled
  45. Untitled
  46. Untitled
  47. Untitled

Used In Evidence Reviews

Similar Papers